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Background: Tamra Bhasma (TB) is one among herbo-metallic preparations extensively used in routine
ayurvedic practice. In the present era, Bhasma preparations used in ayurvedic system of medicines are
always under stern observations for containing heavy metals which may raise the question of safety
aspect.
Objective: In the present study, TB prepared with and without Amritikarana was subjected to toxicity
study to ascertain the role of Amritikarana on safety proﬁle of TB in rats.
Materials and methods: Both the samples of TB were administered to rats for 28 consecutive days at the
doses of 5.5, 27.5, and 55 mg/kg. The effects of both drugs were assessed on ponderal changes, hema-
tological, serum biochemical, and histopathology of various organs.
Results: Results showed that both the samples of TB did not produce any sign and symptoms of toxicity
at therapeutic dose level (5.5 mg/kg) and therapeutic equivalent dose (TED)  5 (27.5 mg/kg) while at
higher dose of TED  10 (55 mg/kg) TB has mild toxicity in liver, kidney, heart, and thymus on repeated
administration for 28 days in rats. The sample without Amritikarana has more magnitude of toxicity than
the sample with Amritikarana.
Conclusion: From the present study, it is concluded that TB with Amritikarana was found to be relatively
safer than TB without Amritikarana at different dose levels in rats and hence suggest for safely use in
humans at therapeutic dose level. It proves the role of Amritikarana in the preparation of TB.
© 2016 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ayurveda advocates therapeutic uses of mineral and metallic
preparations in many diseases since century in clinical practice.
Knowing the possibilities of toxic effects, seers emphasized on
following set of exclusive pharmaceutical procedures such as
Shodhana (puriﬁcation and/or detoxiﬁcation),Marana (incineration
and/or calcination), and Amritikarana that converts the metals and
minerals into Bhasma (calcined powders) [1,2]. Bhasmas are unique
preparations which are safely being practiced in Ayurveda without
any noticeable side effects can be considered as a testimony to their
safety, but no objective veriﬁable data exist to support many suchand Bhaishajya Kalpana, IPGT
8, Gujarat, India.
audhari).
ary University, Bangalore.
lore and World Ayurveda Foundat
es/by-nc-nd/4.0/).claims. Preclinical studies of ayurvedic drug provide scientiﬁc basis
for their traditional use and to prove that they are safe and efﬁca-
cious [3].
Tamra Bhasma (TB) (incinerated copper) is one among such
ayurvedic herbo-metallic preparation used in the treatment of
Udara (ascites), Pandu (anemia), Svasa (asthma), and Amlapitta
(hyperacidity) [4]. Though wide therapeutic utility of TB has been
mentioned in classics, it is reported as poison as ormore than that if
not processed or puriﬁed properly as per classical methods [5]. To
indicate its toxic potential, Ashtamahadoshas (eightmajor ill effects)
have been quoted in classics [6]. Previous studies reported safety of
TB in animal models [7,8]. Role of Shodhana in safety of TB was also
reported in animals [9]. Though number of studies have been car-
ried out in direction of safety of Bhasmas, concerns are always being
raised on ayurvedic formulations for the presence of heavy metals
[10,11]. Amritikarana is exclusively mentioned for TB and Abhrak
Bhasma which is said to eliminate all the blemishes from the endion. Publishing Services by Elsevier B.V. This is an open access article under the CC
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impact of this procedure. Hence, the present study is aimed to
evaluate the acute and subchronic toxicity studies of TB prepared
with and without Amritikarana in rats.
2. Materials and methods
2.1. Drugs and chemicals
Two samples of TB with and without Amritikarana were pre-
pared by following standard guidelines as prescribed in ayurvedic
classics. Copper scraps with 99.89% pure copper was procured from
local industrial area, Jamnagar, India. It was subjected to general
and speciﬁc puriﬁcation procedure followed by incineration after
mixed with puriﬁed sulfur, Kajjali (black sulﬁde of mercury), and
juice of Citrus jambhiri Lush. In Amritikarana, it was mixed with half
part puriﬁed sulfur and juice of C. jambhiri Lush, kept in the corm of
Amorphophallus campanulatus Linn. It was subjected to heat treat-
ment and labeled as Tamra Bhasma with Amritikarana (TBA) [12].
Another sample was subjected up to Marana and labeled as TB
without Amritikarana [13]. All chemicals used in the study were of
analytical grade.
2.2. Animals
Wistar strain albino rats of either sex, weighing 200 ± 20 g, were
used as per the guidelines of the Institutional Animal Ethics Com-
mittee (IAEC). The animals were obtained from the animal house
attached to the pharmacology laboratory, IPGT and RA, Jamnagar.
The animals were maintained under ideal husbandry conditions in
terms of standard conditions of temperature (23 ± 2 C), relative
humidity (50e60%) and exposed to 12 h light and dark cycles. All
animals were exposed to the same environmental conditions and
were maintained on standard diet and drinking water ad libitum.
The experimental protocol was approved by the IAEC/14/2013/16 as
per guideline of committee for the purpose of control and super-
vision of experiments on animals in India.
2.3. Dose ﬁxation
As per classical guideline, the therapeutic clinical dose of TB is
30 mg twice a day (60 mg/day) [14]. The suitable dose for rats was
calculated by referring to table of Paget and Branes [15] and was
found to be 5.5 mg/kg body weight of rat (considered as TED). The
test drug was administered orally (licking) along with honey as
adjuvant with the help of oral cannula.
2.4. Acute toxicity study
Young, healthy, nulliparous, and nonpregnant Wistar strain al-
bino female rats were selected and acclimatized for 7 days before
the experiment. Both test drugs along with adjuvant were orally
administered at limit dose of 2000 mg/kg to overnight fasted fe-
male rats by following Organization for Economic Cooperation and
Development (OECD) 425 guideline [16]. The rats were observed
closely for behavioral changes, signs and symptoms of toxicity, and
mortality, if any continuously for the ﬁrst 6 h and thereafter peri-
odically up to 14 days.
2.5. Subchronic toxicity
Animals were divided into seven groups, each comprising three
male and three females. Rats were randomized into six groups,
each consisting of six rats comprising three male and three female.
Group I was kept as control group, received vehicle as honey (2 ml/kg, orally). Group II to IV were administered with test drug TB
without Amritikarana along with adjuvant at TED (5.5 mg/kg,
orally), TED  5 (27.5 mg/kg, orally), and TED  10 (55.0 mg/kg,
orally), respectively. Group V to VII were administered with test
drug, TBA along with adjuvant at TED (5.5 mg/kg, orally), TED  5
(27.5 mg/kg, orally), and TED 10 (55.0 mg/kg, orally), respectively.
The suspensions of test drugs were administered orally once a day
for 28 consecutive days [17].
Initial body weight of all animals was recorded. General
behavioral pattern was observed once a week by exposing each
animal to open arena. On the 29th day, animals wereweighed again
and anesthetized with diethyl ether. Supraorbital plexus was
punctured under light anesthesia and blood was collected by
capillary in two different types of tubes, one containing anticoag-
ulant ﬂuid for hematological parameters and another plain tube for
serum biochemical investigations. Then, the rats were sacriﬁced
and the abdomen was opened through midline incision to record
the autopsy changes followed by dissecting out the important
organs.
Hematological analysis was performed by using an automatic
hematological analyzer (Swelab, Sweden). Total red blood cell
(TRBC), hemoglobin (Hb), hematocrit, mean corpuscular volume,
mean corpuscular Hb, mean corpuscular Hb concentration, white
blood cell (WBC), neutrophils, lymphocyte percentage, eosinophils
percentage, monocyte percentage, packed cell volume (PCV), and
platelet count were measured from the blood samples.
Serum biochemical parameters were carried out by using fully
automated biochemical random access analyzer (BS-200, Lilac
Medicare Pvt. Ltd., Mumbai). The studied parameters were blood
glucose [18], urea [19], creatinine [20], total cholesterol [21], high-
density lipoprotein (HDL)-cholesterol [22], triglyceride [23], very-
low-density lipoprotein (VLDL)-cholesterol, low-density lipopro-
tein (LDL)-cholesterol, total protein [24], albumin, globulin [25],
alkaline phosphatase [26], serum glutamic oxaloacetic trans-
aminase (SGOT) [27], serum glutamic pyruvic transaminase (SGPT)
[28], uric acid [29], direct bilirubin [28], total bilirubin [30], and
serum calcium [31].
All the important internal organs were carefully dissected
namely, liver, kidney, heart, lungs, trachea, intestine spleen,
thymus, lymph node, testis, seminal vesicle, prostate, uterus, and
ovary. After noting signs of gross lesion and ponderal changes of
major organs, all were transferred to 10% phosphate buffered
formalin solution for ﬁxation and later on subjected to dehydrating,
wax embedding, sectioning, and staining with hematoxylin and
eosin for histological evaluation. The slides were viewed under
trinocular research Carl-Zeiss's microscope at various magniﬁca-
tions to note down the changes in the microscopic features of the
tissues.
2.6. Statistical analysis
The data are expressed as mean ± standard error of mean for six
rats per experimental group. One-way analysis of variance was
used to compare the mean values of quantitative variables among
the groups followed by HolmeSidak multiple t-test for unpaired
data by using Sigmastat software (version 3.5, Systat Software Inc.)
to determine signiﬁcant difference between groups at P < 0.05.
3. Results
3.1. Acute toxicity study
The results of acute toxicity showed that both the samples of TB
along with adjuvant did not affect any behavioral changes and
other parameters during entire experimental period of 14 days.
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and mortality when given orally at a dose of 2000 mg/kg.
3.2. Subchronic toxicity study
Behavioral changes were not observed in treated groups during
the course of subchronic toxicity study in comparison to control
group. No mortality was observed in both samples of TB at
TED  10, TED  5, and TED dose levels during the experimental
period.
Weight gain was observed in normal control rats during sub-
chronic toxicity study. Effects of TB and TBA on change in body
weight showed that weight gainwas observed in all treated groups,
but percentage change in bodyweight pattern in treated groups did
not differ signiﬁcantly from the changes observed in control groups
[Table 1]. Subchronic administration of TB at different dose levels
lead to nonsigniﬁcant effect on change in relative weight of nine
organs except signiﬁcant increase was observed in relative weight
of heart in TBA at TED level [Table 2]. TBA at all dose levels produced
nonsigniﬁcant increase in relative weight of thymus, spleen, and
testis in a uniformmanner while other changes were not distinct in
comparison to control group.
Effect of samples of TB on hematological parameters [Table 2]
revealed that out of the twelve parameters studied, nonsigniﬁcant
increase in WBC count and neutrophil in TB at TED  10 dose level
while signiﬁcant increase in monocyte count in TB at TED  5 dose
level in comparison to control group. Signiﬁcant increase in Hb,
PCV, and TRBC were observed in TB and TBA treated groups at TED
and TED  5 dose levels [Table 3]. Both samples of TB at all dose
levels produced nonsigniﬁcant increase in platelet count in com-
parison to control group.
Among the 18 serum biochemical parameters, signiﬁcant
decrease in blood sugar was found in TB at TED dose level and TBA
treated drug at TED  5 and TED  10 levels, while signiﬁcant in-
crease in cholesterol was found in TB and TBA treated groups at TED
and TED  5 dose levels, while higher dose of both drugs produced
nonsigniﬁcant increase in serum cholesterol level. Signiﬁcant in-
crease in serum triglyceride, LDL, and VLDL level was found in TB at
TED  10 treated groups while nonsigniﬁcant increase in triglyc-
eride and VLDL level in all TBA treated groups in comparison to
control group. HDL cholesterol was signiﬁcantly increased in TB
treated group at TED dose level and TBA treated group at TED and
TED  5 treated groups while both at higher dose levels produced
nonsigniﬁcant increase in comparison to control group. Signiﬁcant
increase in albuminwas observed at all dose levels of TB and higher
dose level of TBA. The changes observed in remaining biochemical
parameters were statistically nonsigniﬁcant in comparison to
control group [Table 4].
Microscopic examination of all the organs obtained from control
group exhibited normal cytoarchitecture. TB with and without
Amritikarana at TED  10 dose level did not affect the cytoarchi-
tecture of the spleen, lung, stomach, lymph node, trachea, adrenal,Table 1
Effect of Tamra Bhasma on body weight of albino rats.
Groups 0 day 1st week
Control 210.66 ± 11.02 233.33 ± 12.29***
TB TED 194.33 ± 9.58 210.33 ± 10.07
TB TED  5 187.66 ± 10.99 205.66 ± 14.88*
TB TED  10 206.00 ± 9.71 216.33 ± 8.57
TBA TED 182.33 ± 8.00 193.33 ± 7.14**
TBA TED  5 186.66 ± 9.54 195.33 ± 8.43**
TBA TED  10 195.33 ± 9.95 212.33 ± 9.38
Data presented asmean ± SEM, *P < 0.05, **P< 0.01, ***P< 0.001 (paired t-test). SEM¼ Sta
Amritikarana, TBA ¼ Tamra Bhasma with Amritikarana.prostate, seminal vesicle, testis, ovary, and uterus. Administration
of TB at TED  10 causes mild fatty changes in the heart but TBA at
TED 10 showed normal cytoarchitecture [Fig. 1], while both drugs
at higher dose level showed micro fatty changes in liver [Fig. 2].
Mild cell inﬁltration and edema in the kidney in TB at TED  10,
while mild fatty changes in TBA at TED 10 dose level [Fig. 3] were
observed and both drugs at higher dose produced mild decrease in
cellularity in cytoarchitecture of thymus [Fig. 4]. However, all these
changes were not observed in both the drugs treated groups at
TED 5 and TED dose levels in rats that suggest that drug is devoid
of drastic toxicity.
4. Discussion
Metals and minerals are extensively used in ayurvedic formu-
lations since Vedic period, which became an important part of
ayurvedic therapeutics. To make them for therapeutic use, they
have to pass through a set of classical pharmaceutical processes
known as Shodhana, Marana, etc. The possible impurities that
remain in Bhasma after Marana process are advocated to be
removed by another specialized procedure known as Amritikarana.
[32] In classics, it is mentioned that Amritikarana increases thera-
peutic efﬁcacy of Bhasma [33]. The word, Amritikarana itself ex-
plains the importance of this procedure, i.e., the process by which
Amrititva is imparted to the matter. This procedure is recom-
mended for all the Bhasmas but claimed to be essential mainly in
Abhraka and TB. It should be done after conﬁrmation of Bhasma
Siddha Lakshanas. In this process, quality of Bhasma increases along
with change in regular color and appearance.
Acute toxicity was carried out to record immediate adverse signs
and symptoms after the administration of single dose of drug at dose
levels that are several folds higher than the therapeutic equivalent
dose (2000 mg/kg). OECD 425 guideline for oral acute toxicity study
were employed using a female sex to reduce variability and as a
means of minimizing the number of animals used. This is because
there is little difference in sensitivity in LD50 test between the sexes;
however, in those cases where differences were observed, females
were generally slightly more sensitive [34]. In this study, TB s at the
dose level of 2000mg/kg, orally didnot produce anyobservable toxic
effects during the entire duration of acute toxicity study and all fe-
male rats survived 14 days of observation suggest that LD50 value
may be higher than 2000 mg/kg by oral route. As per UN classiﬁca-
tion, any substance which has oral LD50 of more than 2000 mg/kg is
considered as low hazard potential and categorized as UN 6.1 PG III
[35]. Thus, as per the above criterion, both TB with or without
Amritikarana can be categorized as substances with low health
hazard potential (Class 4 of GHS and UN 6.1 PG III).
On subchronic administration of TB with or without Amritikar-
ana showed signiﬁcant increase in Hb, red blood cell (RBC) and PCV
but not found to be in dose-dependent manner. In the present
study, increased Hb content is due to the increase observed in the
production of erythrocytes and PCV in these treated groups.2nd week 3rd week 4th week
239.33 ± 11.73*** 262.00 ± 9.94* 241.66 ± 6.58**
213.33 ± 9.24* 213.33 ± 9.78 212.66 ± 10.97
208.66 ± 13.38* 205.00 ± 12.31 210.00 ± 17.88*
222.33 ± 12.81 228.83 ± 12.51* 232.33 ± 16.37*
206.66 ± 7.13** 221.33 ± 11.12* 206.66 ± 12.561
205.00 ± 8.46*** 224.00 ± 5.61** 213.33 ± 4.21
216.33 ± 9.45*** 222.33 ± 10.39** 221.66 ± 13.76*
ndard error ofmean, TED¼ Therapeutic equivalent dose, TB¼ Tamra Bhasmawithout
Table 2
Effect of Tamra Bhasma samples on relative weight of organs.
Relative weight Control group Tamra Bhasma without Amritikarana Tamra Bhasma with Amritikarana
TED TED  5 TED  10 TED TED  5 TED  10
Heart (mg/100 g) 284.26 ± 10.97 290.55 ± 9.30 307.29 ± 12.75 276.12 ± 15.86 332.00 ± 12.77* 310.26 ± 13.37 302.70 ± 14.89
Liver (g/100 g) 3.06 ± 0.17 2.97 ± 0.12 3.22 ± 0.13 3.10 ± 0.06 2.96 ± 0.21 3.45 ± 0.13 3.24 ± 0.13
Spleen (mg/100 g) 201.01 ± 10.72 200.78 ± 13.26 212.09 ± 12.96 211.56 ± 12.84 235.79 ± 13.78 235.77 ± 16.61 215.35 ± 12.04
Kidney (mg/100 g) 691.18 ± 17.31 684.25 ± 25.74 751.01 ± 23.38 660.20 ± 28.13 722.47 ± 31.24 734.34 ± 10.94 712.74 ± 27.10
Thymus (mg/100 g) 134.60 ± 27.92 151.61 ± 10.16 168.69 ± 11.68 144.85 ± 12.49 183.18 ± 5.33 176.65 ± 11.15 148.78 ± 12.03
Testis (mg/100 g) 921.62 ± 61.24 1074.91 ± 43.72 1103.66 ± 43.55 857.87 ± 17.64 1071.21 ± 72.44 1113.97 ± 50.34 1082.62 ± 33.57
Prostate (mg/100 g) 158.30 ± 19.87 99.90 ± 11.99 151.89 ± 12.64 96.55 ± 18.57 149.30 ± 20.84 174.13 ± 24.95 117.99 ± 9.22
Uterus (mg/100 g) 252.46 ± 65.42 275.70 ± 58.59 227.10 ± 42.78 230.11 ± 3.16 383.30 ± 105.87 194.96 ± 37.15 228.63 ± 67.33
*P < 0.05 when compared to control group. TED ¼ Therapeutic equivalent dose.
Table 3
Effect of Tamra Bhasma on hematological parameters.
Parameters Control group Tamra Bhasma without Amritikarana Tamra Bhasma with Amritikarana
TED TED  5 TED  10 TED TED  5 TED  10
TWBC (103/mL) 8016.67 ± 526.89 8333.33 ± 463.08 8616.67 ± 633.20 9750.00 ± 1050.95 7333.33 ± 615.18 9250.00 ± 867.85 7916.67 ± 207.23
Neutrophil (%) 22.33 ± 2.42 20.33 ± 2.23 18.33 ± 2.89 26.60 ± 5.16 20.00 ± 4.30 22.00 ± 2.57 24.83 ± 2.24
Lymphocyte (%) 73.17 ± 2.50 75.33 ± 2.12 77.00 ± 2.82 68.40 ± 5.71 76.00 ± 4.62 74.00 ± 2.57 70.33 ± 2.15
Eosinophil (%) 2.67 ± 0.33 2.67 ± 0.33 2.17 ± 0.17 2.80 ± 0.58 2.17 ± 0.31 2.17 ± 0.17 2.83 ± 0.31
Monocyte (%) 1.83 ± 0.17 1.67 ± 0.21 2.50 ± 0.22* 2.20 ± 0.20 1.83 ± 0.31 1.83 ± 0.17 2.00 ± 0.26
Hb (g/dL) 14.37 ± 0.27 15.83 ± 0.27**,@ 15.18 ± 0.35*,@ 14.84 ± 0.30 15.92 ± 0.20***,@ 15.80 ± 0.36*,@ 14.80 ± 0.27
PCV (%) 44.70 ± 1.20 49.40 ± 1.28*,@ 47.57 ± 1.51 46.14 ± 0.84 49.13 ± 0.55**,@ 48.30 ± 0.56*,@ 45.02 ± 0.53
TRBC (106/mL) 7.89 ± 0.25 8.90 ± 0.29*,@ 8.54 ± 0.35 8.33 ± 0.17 8.72 ± 0.13* 8.62 ± 0.16* 8.00 ± 0.11
MCV (fL) 56.70 ± 0.64 55.60 ± 0.67 55.82 ± 0.70 55.40 ± 0.22 56.38 ± 0.40 56.13 ± 0.81 56.32 ± 0.82
MCH (pg/red cell) 18.25 ± 0.33 17.85 ± 0.40 17.87 ± 0.35 17.80 ± 0.37 18.27 ± 0.076 18.07 ± 0.41 18.50 ± 0.42
MCHC (g/dL) 32.18 ± 0.29 32.10 ± 0.41 31.97 ± 0.29 32.18 ± 0.65 32.40 ± 0.24 32.20 ± 0.36 32.90 ± 0.30
Platelets (103/mL) 997.00 ± 143.59 1127.33 ± 23.24 1177.67 ± 88.36 1150.40 ± 101.33 1213.67 ± 66.57 1086.17 ± 34.76 1122.33 ± 61.56
Data presented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 compared to control group (unpaired t-test), @P < 0.05 compared to control group (ANOVA followed by
HolmeSidak test). TED ¼ Therapeutic equivalent dose, SEM ¼ Standard error of mean, TWBC ¼ Total white blood cell, Hb ¼ Hemoglobin, PCV ¼ Packed cell volume,
TRBC ¼ Total red blood cell, MCV ¼ Mean corpuscular volume, MCH ¼ Mean corpuscular hemoglobin, MCHC ¼ Mean corpuscular hemoglobin concentration.
Table 4
Effect of Tamra Bhasma on biochemical parameters.
Parameters NC TB TED TB TED  5 TB TED  10 TBA TED TBA TED  5 TBA TED  10
FBS (mg/dL) 114.33 ± 6.09 86.00 ± 4.38*,@ 102.33 ± 2.46 100.00 ± 6.05 100.33 ± 6.10 97.50 ± 3.66* 94.17 ± 2.60*,@
Serum cholesterol (mg/dL) 47.33 ± 2.59 69.00 ± 6.27*,@ 59.17 ± 4.30* 56.67 ± 5.80 63.17 ± 3.03* 67.00 ± 6.51*,@ 55.33 ± 3.40
Triglycerides (mg/dL) 57.33 ± 4.36 56.67 ± 3.40 57.00 ± 8.41 71.67 ± 4.28* 81.83 ± 11.78 74.83 ± 7.04 76.83 ± 8.50
HDL (mg/dL) 27.83 ± 3.28 41.17 ± 2.27* 35.00 ± 2.73 36.17 ± 3.49 45.00 ± 2.57*,@ 47.00 ± 3.97*,@ 34.50 ± 1.98
LDL (mg/dL) 8.03 ± 1.59 16.50 ± 4.67 12.77 ± 2.11 8.20 ± 1.88 8.33 ± 1.73 7.83 ± 2.71 5.48 ± 1.29
VLDL (mg/dL) 11.47 ± 0.87 11.33 ± 0.68 11.40 ± 1.68 14.37 ± 0.87* 14.28 ± 2.35 14.97 ± 1.41 15.37 ± 1.70
SGPT (IU/L) 56.17 ± 2.50 63.67 ± 5.83 65.83 ± 6.47 65.83 ± 9.22 82.17 ± 28.11 70.67 ± 6.64 60.50 ± 3.53
SGOT (IU/L) 166.00 ± 13.47 171.33 ± 11.04 176.50 ± 13.40 172.00 ± 6.74 162.83 ± 9.99 173.17 ± 13.26 179.67 ± 18.66
ALP (IU/L) 205.67 ± 17.22 170.17 ± 15.49 222.67 ± 26.10 267.83 ± 51.75 206.50 ± 58.21 173.83 ± 36.55 174.33 ± 20.40
Total bilirubin (mg/dL) 0.52 ± 0.07 0.47 ± 0.03 0.57 ± 0.08 1.37 ± 0.83 0.35 ± 0.06 0.37 ± 0.03 0.62 ± 0.08
Direct bilirubin (mg/dL) 0.13 ± 0.02 0.17 ± 0.02 0.13 ± 0.02 0.47 ± 0.32 0.10 ± 0.00 0.10 ± 0.00 0.13 ± 0.02
Blood urea (mg/dL) 62.67 ± 6.06 64.17 ± 4.83 64.50 ± 2.31 59.33 ± 3.22 70.67 ± 4.97 71.67 ± 4.59 61.33 ± 5.10
Creatinin (mg/dL) 0.55 ± 0.034 0.62 ± 0.040 0.57 ± 0.042 0.52 ± 0.017 0.53 ± 0.042 0.55 ± 0.034 0.52 ± 0.040
Protein (g/dL) 6.93 ± 0.20 7.25 ± 0.13 7.02 ± 0.08 6.87 ± 0.14 7.20 ± 0.33 7.18 ± 0.25 7.17 ± 0.25
Albumin (g/dL) 3.38 ± 0.21 3.90 ± 0.08@ 3.83 ± 0.08@ 3.95 ± 0.13*,@ 3.63 ± 0.08 3.77 ± 0.05 3.83 ± 0.09@
Globulin (g/dL) 3.55 ± 0.37 3.35 ± 0.14 3.18 ± 0.14 2.91 ± 0.21 3.57 ± 0.39 3.42 ± 0.25 3.33 ± 0.18
Uric acid (mg/dL) 1.00 ± 0.19 0.87 ± 0.99 0.82 ± 0.09 1.20 ± 0.37 0.97 ± 0.22 0.90 ± 0.19 0.85 ± 0.15
Serum calcium (mg/dL) 8.85 ± 0.15 8.50 ± 0.17 8.78 ± 0.20 9.55 ± 0.33 9.10 ± 0.07 9.35 ± 0.14* 9.18 ± 0.38
Data presented as mean ± SEM, *P < 0.05 compared to control group (unpaired t-test), @P < 0.05 compared to control group (ANOVA followed by HolmeSidak test).
SEM ¼ Standard error of mean, NC ¼ Normal control, FBS ¼ Fasting blood sugar, HDL ¼ High-density lipoprotein, LDL ¼ Low-density lipoprotein, VLDL ¼ Very-low-density
lipoprotein, SGPT¼ Serum glutamic pyruvic transaminase, SGOT¼ Serum glutamic oxaloacetic transaminase, ALP¼ Alkaline phosphatase, TED¼ Therapeutic equivalent dose,
TB ¼ Tamra Bhasma without Amritikarana, TBA ¼ Tamra Bhasma with Amritikarana.
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middle dose level of TB. The fact that the observed effect was not
dose-dependent and is not remarkably deviant from the normal
range of values indicates that they do not indicate any serious
toxicity potential. Previous study also revealed signiﬁcant increase
in total RBC count, PCV, and platelet count at different dose level of
TB on administration for 45 days in albino rats [9]. Copper isessential for the synthesis of Hb and also supports absorption of
iron from intestine, which may responsible for increase in RBC
related parameters in rats [36].
Signiﬁcant decrease in fasting blood sugar at TED level of TB and
higher dose level of TBA suggest role of copper in glucose meta-
bolism. Copper plays important role in carbohydratemetabolism by
stimulating insulin binding, hexose transport, and lipogenesis
Fig. 1. Photomicrographs of sections of the heart taken at 400 (a) normal
cytoarchitecture (control group) (b) fatty changes (Tamra Bhasma therapeutic equiva-
lent dose, 10) (c) normal cytoarchitecture (Tamra Bhasma with Amritikarana thera-
peutic equivalent dose, 10).
Fig. 2. Photomicrographs of sections of the liver taken at 400 (a) normal cytoarch-
itecture (control group) (b) micro fatty changes (Tamra Bhasma therapeutic equivalent
dose, 10) (c) micro fatty changes (Tamra Bhasma with Amritikarana therapeutic
equivalent dose, 10).
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blood sugar level. However, the observed values are still within
normal range [38].
Signiﬁcant increase in cholesterol level was found in TB and TBA
treated groups at TED and TED  5 dose levels while higher dose of
both drugs produced nonsigniﬁcant increase in serum cholesterol
level. Signiﬁcant increase in serum triglyceride, LDL, and VLDL level
was found in TB at TED  10 treated groups while nonsigniﬁcant
increase in triglyceride and VLDL level in all TBA treated groups in
comparison to control group. This suggests that the test drugs may
have effect on cholesterol turnover in the body; however, param-
eters were not affected to signiﬁcant extent at higher dose level in
TBA treated group. Though tendency toward increasing of lipid
proﬁle is seen in TBA treated group, it may not be indicative of any
drastic inﬂuence on lipid metabolism, but TB treated rats prone to
produce hyperlipidemia and related disorders.
HDL-cholesterol was signiﬁcantly increased in TB treated group
at TED dose level and TBA treated group at TED and TED 5 treated
groups while both at higher dose levels produced nonsigniﬁcant
increase in comparison to control group. This activity seen at
therapeutic dose levels in TB and TBA can have good therapeutic
application because elevation of HDL-cholesterol level will be quite
useful in patients with hypercholesterolemia conditions. However,
same was not observed at higher dose levels in both the treated
group.
Parameters related to normal liver functioning such as SGPT,
SGOT, alkaline phosphatase, and bilirubin were not altered to sig-
niﬁcant extent at all dose levels in both treated groups in com-
parison to control group. The values observed were still withinnormal range [38]. Signiﬁcant increase in albumin was observed at
all dose levels of TB and higher dose level of TBA. Albumin is a most
abundant protein in human blood plasma and synthesized in liver
as preproalbumin. However, the values of total protein, globulin,
uric acid, calcium, urea, and creatinine in treated groups and con-
trol group are still within normal range that suggests that both
drugs are devoid of any drastic toxic effect in rats at therapeutic
dose level.
The results of histopathological studies revealed that mild
changes were observed in four visceral organs, i.e., thymus, heart,
liver, and kidney at higher dose level. TBA showed less magnitude
of adverse changes compared to TBwithout Amritikarana. However,
these changes were not observed in both the drug treated groups at
lower dose levels in rats, which suggest that the drug is devoid of
drastic toxicity. Earlier studies with TB also reported safety of the
sample at TED level [9]. Considering this, it can be said that the
Bhasma is safe at TED levels, and mild changes can manifest at
higher dose levels.
Overall, effect of both drugs, TB and TBA at different dose levels
compared with control group. Further, there is no signiﬁcant dif-
ference between TB and TBA treated groups in any of the observed
parameters. TB and TBA produced almost same magnitude of ef-
fect except TB produced changes on alkaline phosphatase, tri-
glyceride, LDL-cholesterol, and total bilirubin. TBA produced more
effect on HDL-cholesterol which may have good therapeutic
application and will be quite useful in patients with hypercho-
lesterolemia conditions. In histopathological observations, TBA
Fig. 3. Photomicrographs of sections of the kidney taken at 400 (a) normal
cytoarchitecture (control group) (b) mild cell inﬁltration and edematous changes
(Tamra Bhasma therapeutic equivalent dose, 10) (c) mild fatty changes (Tamra Bhasma
with Amritikarana therapeutic equivalent dose, 10). Fig. 4. Photomicrographs of sections of the thymus taken at 400 (a) normalcytoarchitecture (control group) (b) mild decrease in cellularity (Tamra Bhasma Ther-
apeutic equivalent dose, 10) (c) mild decrease in cellularity (Tamra Bhasma with
Amritikarana therapeutic equivalent dose, 10).
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produced fatty changes in heart, which was absent in TBA treated
group. Considering all these, it suggests that, though TB is not
much toxic at therapeutic dose level has potential to produced
adverse effects when administered for longer duration at higher
dose levels. Hence, Amritikarana is must for internal administra-
tion of TB.5. Conclusion
From the present study, it is concluded that TBA and TB at
the dose level of 2000 mg/kg, orally did not produce any
observable toxic effects and mortality in acute toxicity study
which suggest that LD50 value may be higher than 2000 mg/kg
by oral route and can be categorized as substances with low
health hazard potential. The results of subchronic toxicity
concluded that TB can be relatively safe at therapeutic dose
levels in rats. However, TB at TED  10 dose level, equivalent of
which are not likely to be ever employed in clinical conditions,
has prone to produce toxic changes in liver, kidney, and heart
and also impact on immune-related organs such as thymus as
revealed by ponderal, hematological, biochemical, and histo-
pathological parameters in rats. At higher dose level, a sample
without Amritikarana has more magnitude of toxicity than the
sample with Amritikarana. This study demonstrates the rational
of Amritikarana in the safety of TB. Hence, it can be inferred that
Amritikarana is must for internal administration of TB in clinical
practices.Source of support
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